Compare JJSF & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | AMLX |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1995 | 2021 |
| Metric | JJSF | AMLX |
|---|---|---|
| Price | $79.57 | $14.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $140.00 | $21.56 |
| AVG Volume (30 Days) | 187.7K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $1,022,038,000.00 | $380,786,000.00 |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $1.70 | N/A |
| P/E Ratio | $603.23 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $68.87 | $4.86 |
| 52 Week High | $129.24 | $18.61 |
| Indicator | JJSF | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 53.00 |
| Support Level | $73.60 | $12.32 |
| Resistance Level | $88.12 | $15.37 |
| Average True Range (ATR) | 2.23 | 0.79 |
| MACD | 0.71 | 0.13 |
| Stochastic Oscillator | 88.24 | 81.78 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.